Cara Therapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference
August 03 2022 - 7:00AM
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage
biopharmaceutical company leading a new treatment paradigm to
improve the lives of patients suffering from pruritus, today
announced that Christopher Posner, President and Chief Executive
Officer, will present at the Canaccord Genuity 42nd Annual Growth
Conference on Wednesday, August 10, 2022, at 9:30 a.m. ET.
A webcast of the presentation can be accessed
under "Events & Presentations" in the News & Investors
section of the Company's website at www.CaraTherapeutics.com. An
archived webcast recording will be available on the Cara website
for approximately 30 days.
About Cara Therapeutics
Cara Therapeutics is a commercial-stage biopharmaceutical
company leading a new treatment paradigm to improve the lives of
patients suffering from pruritus. The Company’s novel KORSUVA™
(difelikefalin) injection is the first and only FDA-approved
treatment for moderate-to-severe pruritus associated with chronic
kidney disease in adults undergoing hemodialysis. The Company is
developing an oral formulation of difelikefalin and has initiated
Phase 3 programs for the treatment of pruritus in patients with
non-dialysis dependent advanced chronic kidney disease and atopic
dermatitis. The Company has completed the placebo-controlled phase
of a Phase 2 proof-of-concept trial of oral difelikefalin for the
treatment of moderate-to-severe pruritus in patients with notalgia
paresthetica. A Phase 2 proof-of-concept trial in primary biliary
cholangitis patients with moderate-to-severe pruritus is ongoing.
For more information, visit www.CaraTherapeutics.com and follow the
company on Twitter, LinkedIn and Instagram.
MEDIA CONTACT:Annie Spinetta6
Degrees973-768-2170aspinetta@6degreespr.com
INVESTOR CONTACT:Iris Francesconi, Ph.D.Cara
Therapeutics203-406-3700investor@caratherapeutics.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Apr 2023 to Apr 2024